Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.

Abstract

This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients undergoing maintenance hemodialysis evaluated the efficacy and safety of combined once-daily oral evocalcet and intravenous vitamin D receptor activator treatment stratified by weekly vitamin D receptor activator dose (117, 45, and 91 patients in no, low [< 1.5 μg], and high [≥ 1.5 μg] dose groups, respectively). Effects of vitamin D receptor activator were assessed on the basis of intact parathyroid hormone, corrected calcium, phosphorus, and fibroblast growth factor-23 levels; percent changes from baseline; proportions of patients who achieved target intact parathyroid hormone, corrected calcium, and phosphorus at Weeks 28-30; and adverse drug reactions. Intact parathyroid hormone, corrected calcium, phosphorus, and fibroblast growth factor-23 levels decreased in all groups; phosphorus and fibroblast growth factor-23 levels remained high in the high dose group. In the low and high dose groups, greater proportions of patients achieved the corrected calcium target compared with the no dose group (p = 0.043). Ratios of intact-to-C-terminal fibroblast growth factor-23 decreased in all groups. In low and high dose groups, hypocalcemia was less common than in the no dose group (p = 0.014). Evocalcet with concomitant vitamin D receptor activator demonstrated benefits such that more patients achieved the corrected calcium target and exhibited decreased fibroblast growth factor-23 synthesis; the incidence of hypocalcemia also decreased. Clinical trial registration: ClinicalTrials.gov (NCT02549391) and JAPIC (JapicCTI-153013).

• Authors: Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa
• Journal: PloS one (PLoS One) Vol. 17 Issue 2 Pg. e0262829 ( 2022) ISSN: 1932-6203 [Electronic] United States
• PMID: 35176038 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Calcimimetic Agents
• Naphthalenes
• Pyrrolidines
• Receptors, Calcitriol
• VDR protein, human
• evocalcet

Topics

• Calcimimetic Agents (therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Humans
• Hyperparathyroidism, Secondary (drug therapy, pathology)
• Male
• Middle Aged
• Naphthalenes (therapeutic use)
• Prognosis
• Pyrrolidines (therapeutic use)
• Receptors, Calcitriol (agonists)